Literature DB >> 19546656

The association between dementia and long-term use of benzodiazepine in the elderly: nested case-control study using claims data.

Chi-Shin Wu1, Sheng-Chang Wang, I-Shou Chang, Keh-Ming Lin.   

Abstract

OBJECTIVES: The aim of this study was to examine the association between long-term benzodiazepines (BZDs) use and the risk of dementia.
DESIGN: Population-based nested case-control study of dementia.
SETTING: All subjects were aged 45 and older and enrolled in the National Health Insurance Research Database in Taiwan, 1997-2004. PARTICIPANTS: Cases (N = 779) were patients who were identified with dementia at least two times in their outpatient claims. They were individually matched to six comparison subjects (N = 4,626) based on age and gender. MEASUREMENTS: BZD usage (average dosage per year, average days per year, and cumulative dose and periods) and potential confounding comobidities, including cardiovascular and psychiatric diseases.
RESULTS: Subjects with dementia had higher cumulative dose, longer duration of BZDs exposure, and more likelihood to be long-term BZDs users.
CONCLUSION: Our findings suggest that long-term use of BZDs is associated with an increased risk for dementia, but the underlying mechanisms remain unclear, and further investigations are needed. Long-term use of BZDs should be avoided among the elderly, who may be at a higher risk for developing dementia, in addition to other health problems.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19546656     DOI: 10.1097/JGP.0b013e3181a65210

Source DB:  PubMed          Journal:  Am J Geriatr Psychiatry        ISSN: 1064-7481            Impact factor:   4.105


  46 in total

1.  Risk factors associated with benzodiazepine use among people who inject drugs in an urban Canadian setting.

Authors:  Devin Tucker; Kanna Hayashi; M-J Milloy; Seonaid Nolan; Huiru Dong; Thomas Kerr; Evan Wood
Journal:  Addict Behav       Date:  2015-10-09       Impact factor: 3.913

Review 2.  Drug interactions with dementia-related pathophysiological pathways worsen or prevent dementia.

Authors:  Romain Barus; Johana Béné; Julie Deguil; Sophie Gautier; Régis Bordet
Journal:  Br J Pharmacol       Date:  2019-03-31       Impact factor: 8.739

3.  Benzodiazepine Use and Risk of Developing Alzheimer's Disease: A Case-Control Study Based on Swiss Claims Data.

Authors:  Fabienne A Biétry; Alena M Pfeil; Oliver Reich; Matthias Schwenkglenks; Christoph R Meier
Journal:  CNS Drugs       Date:  2017-03       Impact factor: 5.749

4.  Hypnotics and the Risks of Dementia.

Authors:  Walter James
Journal:  J Clin Sleep Med       Date:  2017-06-15       Impact factor: 4.062

5.  Benzodiazepine Use and Cognitive Decline in Elderly With Normal Cognition.

Authors:  Yuhai Zhang; Xiao-Hua Zhou; Dana H Meranus; Linbo Wang; Walter A Kukull
Journal:  Alzheimer Dis Assoc Disord       Date:  2016 Apr-Jun       Impact factor: 2.703

6.  Neurocognitive performance, subjective well-being, and psychosocial functioning after benzodiazepine withdrawal in patients with schizophrenia or bipolar disorder: a randomized clinical trial of add-on melatonin versus placebo.

Authors:  Lone Baandrup; Birgitte Fagerlund; Birte Glenthoj
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2016-07-11       Impact factor: 5.270

7.  Benzodiazepine use in Belgian nursing homes: a closer look into indications and dosages.

Authors:  Jolyce Bourgeois; Monique M Elseviers; Majda Azermai; Luc Van Bortel; Mirko Petrovic; Robert R Vander Stichele
Journal:  Eur J Clin Pharmacol       Date:  2011-12-22       Impact factor: 2.953

Review 8.  The Benzodiazepine-Dementia Disorders Link: Current State of Knowledge.

Authors:  Antoine Pariente; Sophie Billioti de Gage; Nicholas Moore; Bernard Bégaud
Journal:  CNS Drugs       Date:  2016-01       Impact factor: 5.749

9.  Benzodiazepines and the potential trophic effect of antidepressants on dentate gyrus cells in mood disorders.

Authors:  Maura Boldrini; Tanya H Butt; Adrienne N Santiago; Hadassah Tamir; Andrew J Dwork; Gorazd B Rosoklija; Victoria Arango; René Hen; J John Mann
Journal:  Int J Neuropsychopharmacol       Date:  2014-06-27       Impact factor: 5.176

Review 10.  Benzodiazepine harm: how can it be reduced?

Authors:  Malcolm Lader
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.